Clinical application value of combined detection of serum miRNA-210 and miRNA-21 in non small cell lung cancer
10.3969/j.issn.1671-8348.2017.07.014
- VernacularTitle:血清miRNA-210和miRNA-21联合检测对NSCLC的临床应用价值
- Author:
Jinlin ZHOU
;
Shukai DENG
- Keywords:
carcinoma,non-small-cell lung;
microRNA;
serum
- From:
Chongqing Medicine
2017;46(7):908-912
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinical value of combined detection of serum miRNA-210 and miRNA-21 in non small cell lung cancer (NSCLC).Methods Forty-eight patients with NSCLC in the Bazhong Municipal Central Hospital were selected as the research subjects.Forty patients with benign lung diseases and 40 individuals undergoing healthy physical examination were selected as the control groups.The levels of serum miRNA-210 and miRNA-21were detected by RT-qPCR.Results The levels of serum miRNA-210 and miRNA-21 in the patients with NSCLC were significantly higher than those in the patients with benign lung diseases and healthy controls(P＜0.05);serum miRNA-210 was highly expressed in adenocarcinoma and T3-4 stage patients(P＜0.05) and miRNA-210 was highly expressed in adenocarcinoma,T3-4 stage and smoking patients(P＜0.05);the area under the ROC curve(AUC) of miRNA-210 and miRNA-21 for diagnosing NSCLC was 0.845 and 0.725 respectively,but AUC of their combination was 0.928 (P =0.021);COX multivariate regression analysis showed that serum miRNA-210 (RR:1.977,95 ％ CI:0.985-3.018,P =0.009) and miRNA-21 (RR:1.853,95％ CI:0.921-2.776,P =0.018) had some predictive value for the prognosis in the patients with NSCLC.Conclusion MiRNA-210 and miRNA-21 are highly expressed in serum of the patients with NSCLC.Their combined detection can have a certain diagnostic efficiency for NSCLC and have a certain prompt action on the prognosis.
